Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharma, leads with Revuforj (menin inhibitor) for relapsed/refractory acute leukemia and Niktimvo (CSF‑1R antibody) for chronic graft‑versus‑host disease, expanding into AML, metastatic CRC and IPF.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 270
HQ: New York

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
SNDX	Syndax Pharmaceuticals Inc. Cap: 1.8B	EQUITY	NMS	USD	US87164F1057	Active	📈